Publication | Closed Access

Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia

Hematological MalignancyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute LeukemiaHematologyPharmacologyPharmacotherapyFirst Induction TherapyOncologyAplastic AnemiaMyeloid Neoplasia